Additional clinical outcomes
At a median follow-up of 37 months (range 11 to 69 months), eight patients had died due to disease progression or complications (Table 3 ). The median overall survival following TPO-RA initiation was 15 months (range: 1-48 months). Five patients relapsed following TPO-RA initiation: three patients with pre-B-ALL, one patient with myelodysplastic syndrome (MDS) that transformed to acute myeloid leukemia (AML) prior to TPO-RA initiation, and one patient with B/Myeloid mixed phenotypic acute leukemia (MPAL). The median relapse-free survival was 6 months (range: 0-46 months). No patients developed a new myeloid malignancy.